HOME > 研究業績 > 2017年- 英語論文

2017年- 英語論文

1. Furukawa K, Tomita N, Uematsu D, Okahara K, Shimada H, Ikeda M, Matsui T, Kozaki K, Fujii M, Ogawa T, Umegaki H, Urakami K, Nomura H, Kobayashi N, Nakanishi A, Washimi Y, Yonezawa H, Takahashi S, Kubota M, Wakutani Y, Ito D, Sasaki T, Matsubara E, Une K, Ishiki A, Yahagi Y, Shoji M, Sato H, Terayama Y, Kuzuya M, Araki N, Kodama M, Yamaguchi T, Arai H. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease. Geriatr Gerontol Int. 2017 Feb;17(2):211-218. doi: 10.1111/ggi.12696. Epub 2015 Dec 29.

2. Ishiki A, Harada R, Okamura N, Tomita N, Christopher C. Rowe, Victor L. Villemagne, Yanai K, Kudo Y, Arai H, Furumoto S, Tashiro M, Furukawa K. “Tau imaging with 18F-THK5351 in progressive supranuclear palsy”. European Journal of Neurology Wiley, 2017 Jan;25(1):130-136, DOI: 10.1111/ene.13164

3. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Miyata S, Arai H, Taki Y, Furukawa K, Fukumoto Y, Shimokawa H. Reduced brain-derived neurotrophic factor is associated with cognitive dysfunction in patients with chronic heart failure. Geriatr Gerontol Int. 2017 May;17(5):852-854. doi: 10.1111/ggi.12959.

4 .Harada R, Furumoto S, Tago T, Furukawa K, Ishiki A, Tomita N, Iwata R, Tashiro M, Arai H, Yanai K, Kudo Y, Okamura N. Erratum to: Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):177.

5. Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, Tago T, Tomita N, Watanuki S, Hiraoka K, Ishikawa Y, Funaki Y, Nakamura T, Yoshikawa T, Iwata R, Tashiro M, Sasano H, Kitamoto T, Yanai K, Arai H, Kudo Y, Okamura N. Correlations of 18F-THK5351 PET with post-mortem burden of tau and astrogliosis in Alzheimer's disease. J Nucl Med. 2017 Sep 1. pii: jnumed.117.197426. doi: 10.2967/jnumed.117.197426. [Epub ahead of print]

6. Kok Pin Ng, Tharick A. Pascoal, Sulantha Mathotaarachchi, Joseph Therriault, Min Su Kang, Monica Shin, Marie-Christine Guiot, Qi Guo, Ryuichi Harada, Robert A. Comley, Gassan Massarweh, Jean-Paul Soucy, Nobuyuki Okamura, Serge Gauthier, Pedro Rossa-Neto, “Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain”, Alzheimer’s Research & Therapy, 2017 9:25

7 .Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, Nag S, Tian H, Ghetti B, Okamura N, Higuchi M, Halldin C, Nordberg A. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017; 9: 96.

8. Naganuma F, Nakamura T, Yoshikawa T, Iida T, Miura Y, Karpati A, Matsuzawa T, Yanai A, Mogi A, Mochizuki T, Okamura N, Yanai K. Histamine N-methyltransferase regulates aggression and the sleep-wake cycle. Sci Rep. 2017; 7: 15899.

9. Betthauser TJ, Ellison PA, Murali D, Lao PJ, Barnhart TE, Furumoto S, Okamura N, Johnson SC, Engle JW, Nickles RJ, Christian BT. Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau. Appl Radiat Isot. 2017; 130: 230-237.

10. Lee H, Seo S, Lee SY, Jeong HJ, Woo SH, Lee KM, Lee YB, Park KH, Heo JH, Yoon CW, Kang JM, Cho J, Okamura N, Furumoto S, Yanai K, Na DL, Ido T, Villemagne VL, Noh Y. [18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia. Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):62-69. doi: 10.1097/WAD.0000000000000216.

11. Kang JM, Lee SY, Seo S, Jeong HJ, Woo SH, Lee H, Lee YB, Yeon BK, Shin DH, Park KH, Kang H, Okamura N, Furumoto S, Yanai K, Villemagne VL, Seong JK, Na DL, Ido T, Cho J, Lee KM, Noh Y. Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. Neurobiol Aging. 2017; 59: 210-219.

12. Sone D, Imabayashi E, Maikusa N, Okamura N, Furumoto S, Kudo Y, Ogawa M, Takano H, Yokoi Y, Sakata M, Tsukamoto T, Kato K, Matsuda H. Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease: A combined positron emission tomography/magnetic resonance imaging study. Alzheimers Dement (Amst). 2017; 9: 35-40.

13. Shidahara M, Thomas BA, Okamura N, Ibaraki M, Matsubara K, Oyama S, Ishikawa Y, Watanuki S, Iwata R, Furumoto S, Tashiro M, Yanai K, Gonda K, Watabe H. A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [18F]THK5351 and [11C]PIB. Ann Nucl Med. 2017; 31: 563-569.

14. Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017; 9: 25.

15. Hsiao IT, Lin KJ, Huang KL, Huang CC, Chen HS, Wey SP, Yen TC, Okamura N, Hsu JL. Biodistribution and radiation dosimetry for the tau tracer 18F-THK-5351 in healthy human subjects. J Nucl Med. 2017; 58:1498-1503.

16. de Leon MJ, Li Y, Okamura N, Tsui WH, Saint Louis LA, Glodzik L, Osorio RS, Fortea J, Butler T, Pirraglia E, Fossati S, Kim HJ, Carare RO, Nedergaard M, Benveniste H, Rusinek H. CSF clearance in Alzheimer Disease measured with dynamic PET. J Nucl Med. 2017; 58: 1471-1476.

17. Okamura N, Yanai K. Brain imaging: Applications of tau PET imaging. Nat Rev Neurol. 2017; 13: 197-198.

18. Furumoto S, Tago T, Harada R, Kudo Y, Okamura N. 18F-Labeled 2-arylquinoline derivatives for tau imaging: chemical, radiochemical, biological and clinical features. Curr Alzheimer Res. 2017; 14: 178-185.

19. Arakawa Y, Nai Y, Shidahara M, Furumoto S, Seki C, Okamura N, Tashiro M, Kudo Y, Yanai K, Gonda K, Watabe H. Prediction of the clinical standardized uptake value ratio in amyloid PET imaging using a biomathematical modeling approach towards the efficient development of a radioligand. J Nucl Med. 2017; 58: 1285-1292.

20. Neelamegam R, Yokell DL, Rice PA, Furumoto S, Kudo Y, Okamura N, El Fakhri G. A report of the automated radiosynthesis of the tau PET radiopharmaceutical, [18F]-THK-5351. J Labelled Comp Radiopharm. 2017; 60: 140-146.

21 .Betthauser T, Lao PJ, Murali D, Barnhart TE, Furumoto S, Okamura N, Stone CK, Johnson SC, Christian BT. In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317. J Nucl Med. 2017; 58: 996-1002.

22. M Brendel, S Schonecker, G Hoglinger, S Lindner, J Havla, J Blautzik, J Sauerbeck, G Rohrer, C Zach, F Vettermann, A E. Lang, L Golbe, G Nubling, P Bartenstein, K Furukawa, A Ishiki, K Botzel, A Danek, N Okamura, J Levin, A Rominger. [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. Front. Aging Neurosci. 17 January 2018. doi: 10.3389/fnagi.2017.00440

23. Takamatsu Y, Ho G, Shimizu Y, Sugama S, Takenouchi T, Waragai M, Wei J, Hashimoto M. Potential Application of Centrifuges to Protect the CNS in Space andon Earth. Curr Alzheimer Res. 2017 Dec 29. doi:10.2174/1567205015666171229225501. [Epub ahead of print] PubMed PMID: 29298650.

24. Waragai M, Moriya M, Nojo T. Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study. J Alzheimers Dis. 2017;60(4):1411-1427. doi: 10.3233/JAD-170450. PubMedPMID: 28968236; PubMed Central PMCID: PMC5676849.

25. Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, Kondo M, Allsop D, Tokuda T. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegener. 2017 Sep 4;12(1):63. doi:10.1186/s13024-017-0206-8. PubMed PMID: 28866979; PubMed Central PMCID: PMC5582385.

26. Higashi K, Shibasaki M, Kuni K, Uemura T, Waragai M, Uemura K, Igarashi K, Toida T. Determination of 3-hydroxypropylmercapturic acid in urine by three column-switching high-performance liquid chromatography with electrochemicaldetection using a diamond electrode. J Chromatogr A. 2017 Sep 29;1517:79-85. doi: 10.1016/j.chroma.2017.08.030. Epub 2017 Aug 26. PubMed PMID: 28851527.

27. Waragai M, Ho G, Takamatsu Y, Sekiyama K, Sugama S, Takenouchi T, Masliah E, Hashimoto M. Importance of adiponectin activity in the pathogenesis of Alzheimer's disease. Ann Clin Transl Neurol. 2017 Jul 11;4(8):591-600. doi:10.1002/acn3.436. eCollection 2017 Aug. Review. PubMed PMID: 28812049; PubMed Central PMCID: PMC5553221.

28. Tsukamoto H, Yamagata Y, Ukai I, Takeuchi S, Okubo M, Kobayashi Y, Kozakai S, Kubota K, Numasaki M, Kanemitsu Y, Matsumoto Y, Tomioka Y. An inhibitory epitope of human Toll-like receptor 4 resides on leucine-rich repeat 13 and is recognized by a monoclonal antibody. FEBS Lett. 2017 Sep;591(18):2953. doi: 10.1002/1873-3468.12837